Literature DB >> 31233766

Histamine beyond its effects on allergy: Potential therapeutic benefits for the treatment of Amyotrophic Lateral Sclerosis (ALS).

Cinzia Volonté1, Savina Apolloni2, Mario Sabatelli3.   

Abstract

ALS currently remains a challenge despite many efforts in performing successful clinical trials and formulating therapeutic solutions. By learning from current failures and striving for success, scientists and clinicians are checking every possibility to search for missing hints and efficacious treatments. Because the disease is very complex and heterogeneous and, moreover, targeting not only motor neurons but also several different cell types including muscle, glial, and immune cells, the right answer to ALS is conceivably a multidrug strategy or the use of broad-spectrum molecules. The aim of the present work is to gather evidence about novel perspectives on ALS pathogenesis and to present recent and innovative paradigms for therapy. In particular, we describe how an old molecule possessing immunomodulatory and neuroprotective functions beyond its recognized effects on allergy, histamine, might have a renewed and far-reaching momentum in ALS.
Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ALS; Histamine; Microglia; Motor neuron; Neuroinflammation; Personalized medicine; SOD1-G93A

Mesh:

Substances:

Year:  2019        PMID: 31233766     DOI: 10.1016/j.pharmthera.2019.06.006

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  10 in total

1.  Influence of GSTP1 rs1695 polymorphism on survival in male patients' amyotrophic lateral sclerosis: a genetic association study in Brazilian population.

Authors:  Rodrigo da Silva Santos; Angela Adamski da Silva Reis; Jéssica Barletto de Sousa Barros; Kamilla de Faria Santos; Dhiogo da Cruz Pereira Bento; Leandro do Prado Assunção
Journal:  Mol Biol Rep       Date:  2021-10-08       Impact factor: 2.316

2.  The Histamine and Multiple Sclerosis Alliance: Pleiotropic Actions and Functional Validation.

Authors:  Cinzia Volonté; Savina Apolloni; Susanna Amadio
Journal:  Curr Top Behav Neurosci       Date:  2022

Review 3.  Histamine and Microglia.

Authors:  Tomomitsu Iida; Kazuhiko Yanai; Takeo Yoshikawa
Journal:  Curr Top Behav Neurosci       Date:  2022

Review 4.  Revisiting Preclinical Observations of Several Histamine H3 Receptor Antagonists/Inverse Agonists in Cognitive Impairment, Anxiety, Depression, and Sleep-Wake Cycle Disorder.

Authors:  Mera Alhusaini; Nermin Eissa; Ali K Saad; Rami Beiram; Bassem Sadek
Journal:  Front Pharmacol       Date:  2022-06-01       Impact factor: 5.988

5.  Repurposing Histaminergic Drugs in Multiple Sclerosis.

Authors:  Susanna Amadio; Federica Conte; Giorgia Esposito; Giulia Fiscon; Paola Paci; Cinzia Volonté
Journal:  Int J Mol Sci       Date:  2022-06-06       Impact factor: 6.208

Review 6.  The Multifaceted Role of GPCRs in Amyotrophic Lateral Sclerosis: A New Therapeutic Perspective?

Authors:  Davide Bassani; Matteo Pavan; Stephanie Federico; Giampiero Spalluto; Mattia Sturlese; Stefano Moro
Journal:  Int J Mol Sci       Date:  2022-04-19       Impact factor: 6.208

Review 7.  Fly for ALS: Drosophila modeling on the route to amyotrophic lateral sclerosis modifiers.

Authors:  Francesco Liguori; Susanna Amadio; Cinzia Volonté
Journal:  Cell Mol Life Sci       Date:  2021-07-28       Impact factor: 9.261

8.  Drug Repurposing: A Network-based Approach to Amyotrophic Lateral Sclerosis.

Authors:  Giulia Fiscon; Federica Conte; Susanna Amadio; Cinzia Volonté; Paola Paci
Journal:  Neurotherapeutics       Date:  2021-05-13       Impact factor: 6.088

Review 9.  Klotho Pathways, Myelination Disorders, Neurodegenerative Diseases, and Epigenetic Drugs.

Authors:  Walter H Moos; Douglas V Faller; Ioannis P Glavas; David N Harpp; Iphigenia Kanara; Anastasios N Mavrakis; Julie Pernokas; Mark Pernokas; Carl A Pinkert; Whitney R Powers; Konstantina Sampani; Kosta Steliou; Demetrios G Vavvas; Robert J Zamboni; Krishna Kodukula; Xiaohong Chen
Journal:  Biores Open Access       Date:  2020-03-31

Review 10.  Advances in nanotechnology-based strategies for the treatments of amyotrophic lateral sclerosis.

Authors:  G Y Wang; S L Rayner; R Chung; B Y Shi; X J Liang
Journal:  Mater Today Bio       Date:  2020-05-04
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.